Review
Medicine, General & Internal
Seong Hyeon Yu, Seung Il Jung
Summary: Historically, urine was believed to be sterile, but recent studies have shown the presence of bacteria and microbial DNA in urine. This article focuses on the evidence of a microbial presence in urine and its association with lower urinary tract symptoms, particularly in men with benign prostate hyperplasia (BPH).
Article
Urology & Nephrology
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Ilona Csizmadi, Stephen J. Freedland
Summary: This study analyzed the association between statin use and the incidence of LUTS in asymptomatic men, as well as the progression of LUTS in symptomatic men. The results showed no significant relationship between statin use and either LUTS incidence or progression. Therefore, statins do not appear to play a role in the prevention or management of LUTS.
JOURNAL OF UROLOGY
(2022)
Article
Endocrinology & Metabolism
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Stephen J. Freedland, Ilona Csizmadi
Summary: In older men, smoking does not increase the risk of developing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in asymptomatic men, nor does it affect the progression of LUTS in symptomatic men.
Review
Medicine, General & Internal
Francesco Sessa, Paolo Polverino, Giampaolo Siena, Claudio Bisegna, Mattia Lo Re, Pietro Spatafora, Alessio Pecoraro, Anna Rivetti, Luisa Moscardi, Marco Saladino, Andrea Cocci, Mauro Gacci, Vincenzo Li Marzi, Marco Carini, Andrea Minervini, Riccardo Campi, Sergio Serni
Summary: The article reviewed the current evidence on surgical and functional outcomes of Transperineal Laser Ablation (TPLA) for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). A total of seven single-arm, non-comparative studies were included in the review. Functional outcomes were assessed using uroflowmetry parameters and validated questionnaires. The review found promising short- and mid-term effectiveness of TPLA, but noted a lack of standardized pathways for patient assessment and technical variations in the procedure across published series.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Caihong Xin, Huaying Fan, Jing Xie, Jingcheng Hu, Xin Sun, Qiuchen Liu
Summary: This systematic review evaluated the impact of diabetes mellitus on lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) patients. The results of the meta-analysis supported that LUTS in BPH patients were increased in patients with diabetes mellitus compared with controls, suggesting that physicians should pay more attention to BPH patients with diabetes mellitus.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Medicine, General & Internal
Giulio Milanese, Edoardo Agostini, Maria Vittoria De Angelis, Eugenio Pretore, Andrea Benedetto Galosi, Daniele Castellani
Summary: The study aimed to evaluate the impact of Cavacurmin(R) on prostate volume (PV), lower urinary tract symptoms (LUTS), and micturition parameters in men after 1 year of therapy. The retrospective comparison of 20 men receiving alpha 1-adrenoceptor antagonists plus Cavacurmin(R) with 20 men receiving only alpha 1-adrenoceptor antagonists revealed that the combination therapy led to significantly lower PV, PSA, and IPSS levels, as well as higher Qmax values.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Andrology
Yumeng Chai, Zhongbao Zhou, Yuanshan Cui, Xuanyan Che, Yong Zhang
Summary: The study conducted a systematic review and meta-analysis on the outcomes and complications of naftopidil in elderly men with BPH-related LUTS, compared to tamsulosin. The results showed that naftopidil had comparable efficacy and similar incidence of adverse events as tamsulosin, indicating it as a promising alternative. However, more high-quality and long-term prospective trials are necessary to confirm these findings.
Article
Radiology, Nuclear Medicine & Medical Imaging
Thomas H. Sanford, Stephanie A. Harmon, Deepak Kesani, Sandeep Gurram, Nikhil Gupta, Sherif Mehralivand, Jonathan Sackett, Scott Wiener, Bradford J. Wood, Sheng Xu, Peter A. Pinto, Peter L. Choyke, Baris Turkbey
Summary: The study aimed to quantitatively assess prostate anatomy and its relation to lower urinary tract symptoms. Prostatic urethral length was found to be associated with worse urinary symptoms, along with urethral angle and transition zone volume. This demonstrates the potential of quantitative assessment of prostatic urethral anatomy in predicting lower urinary tract symptoms.
ACADEMIC RADIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Zhinan Fan, Hongjin Shi, Jinsong Zhang, Haifeng Wang, Jiansong Wang
Summary: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) are common in middle-aged and elderly men. Different drug regimens have varying efficacy in treating BPH/LUTS, with combination therapy showing greater effectiveness in improving symptom scores and maximum flow rates compared to monotherapy. However, current treatment plans have no significant effect on reducing post-void residual urine.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Jianming Guo, Rong Fang
Summary: This meta-analysis indicates that doxazosin-GITS has significantly higher efficacy and lower adverse events compared to tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia, based on data from 8 eligible randomized controlled trials.
Article
Urology & Nephrology
Charles Welliver, Lydia Feinstein, Julia B. Ward, Ziya Kirkali, Erline Martinez-Miller, Brian R. Matlaga, Kevin McVary
Summary: The study aimed to define costs related to lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) care. The findings showed that the medical expenses for LUTS/BPH increased over the years, with outpatient fees in healthcare facilities gradually rising while inpatient charges decreased. The estimated total direct costs for LUTS/BPH in 2013 were at least $1.9 billion.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2022)
Article
Andrology
Seong Yu, Do Lim, Sun-Ouck Kim
Summary: This study investigated the association between periurethral calcification (PUC) and uroflowmetric parameters and symptom severity in male patients with lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). The data was collected from a database of 1321 men with LUTS of BPH. The study found that PUC was significantly associated with worse LUTS parameters, including higher International Prostate Symptom Score (IPSS) and lower peak flow rate (Qmax).
ASIAN JOURNAL OF ANDROLOGY
(2023)
Article
Medicine, General & Internal
Romaric Loffroy, Kevin Guillen, Etienne Salet, Clement Marcelin, Pierre-Olivier Comby, Marco Midulla, Nicolas Grenier, Olivier Chevallier, Francois Petitpierre
Summary: Prostate artery embolization (PAE) with N-butyl cyanoacrylate (NBCA) glue as the embolic agent is feasible, safe, fast, and effective for patients with benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTSs). Significant improvements were observed in prostate symptoms and quality of life outcomes in the short term following the treatment.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Urology & Nephrology
Edoardo Pozzi, Luca Boeri, Paolo Capogrosso, Walter Cazzaniga, Luigi Candela, Giuseppe Fallara, Nicolo Schifano, Antonio Costa, Daniele Cignoli, Manuela Tutolo, Rayan Matloob, Costantino Abbate, Francesco Montorsi, Andrea Salonia
Summary: The Overactive Bladder questionnaire (OABq) can detect additional storage lower urinary tract symptoms (LUTS) in patients presenting solely with voiding LUTS according to the IPSS questionnaire. Moreover, the OABq is associated with worse quality of life in these patients regardless of the severity of voiding symptoms.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Urology & Nephrology
Naoki Wada, Noriyuki Abe, Kotona Miyauchi, Mayumi Ishikawa, Shogo Makino, Hidehiro Kakizaki
Summary: The study identified that patients with larger prostate volume and lower voiding efficiency are more likely to experience treatment failure with dutasteride add-on treatment to alpha-adrenergic antagonist. Intravesical prostatic protrusion (IPP) ≥ 13 mm was found to be a risk factor for treatment failure.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2022)
